Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Innovative approaches to conducting proof-of-concept trials could accelerate the evaluation of repurposed drugs. Drawing lessons from repurposing efforts for COVID-19 therapies, here we present a vision for a drug repurposing platform that could maximize efficiency and improve patient outcomes for many different conditions.
Astellas’s claudin-18.2-targeted antibody zolbetuximab provides a benefit in hard-to-treat metastatic gastric cancer, and leads a multi-modality herd of contenders.
Vividion CEO Aleksandra Rizo discusses emerging lessons from the firm’s use of fragment-based screening — including the potential for allosteric covalent drugs to drive different functional effects through a single binding site.
DNA-encoded library (DEL) technology is a powerful small-molecule discovery platform, offering many advantages over traditional screening methods. Here, Peterson and Liu provide an in-depth review of recent small molecules discovered through DELs, illustrating the versatility, efficiency and broad impact of this technology.
Several forms of non-apoptotic cell death, such as necroptosis, pyroptosis, parthanatos and ferroptosis, are implicated in degenerative diseases, cancer and inflammation. This article describes the molecular pathways regulating these forms of cell death and gives an update on small-molecule inhibitors being developed to target these pathways.
Increased understanding of the molecular mechanisms underlying type 2 chronic inflammatory diseases has facilitated the development of more targeted therapies for these conditions. Focusing on five major type 2 diseases, this Review provides an overview of the pathogenic drivers of type 2 inflammation, assesses agents that target them and considers emerging novel therapies and unmet needs.